Intelligence Feed event · Equity · 2026-09-03

    Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million

    Question

    Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million

    Direct answer

    Fortrea announced a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The transaction expands Fortrea's early clinical development footprint, adding a GLP-compliant bioanalytical lab in Austin, a 200-bed clinical pharmacology facility in San Antonio, and specimen storage assets in Pflugerville, Texas.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/fortrea-to-acquire-worldwide-clinical-trials-early-phase-division-for-45-million-7db9e4

    EQUITY
    Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
    Fortrea announced a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The transaction expands Fortrea's early clinical development footprint, adding a GLP-compliant bioanalytical lab in Austin, a 200-bed clinical pharmacology facility in San Antonio, and specimen storage assets in Pflugerville, Texas.
    FTRE
    Impact
    61
    SEP 3
    SIG
    85%
    FTRE
    Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
    Fortrea announced a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The transaction expands Fortrea's early clinical development footprint, adding a GLP-compliant bioanalytical lab in Austin, a 200-bed clinical pharmacology facility in San Antonio, and specimen storage assets in Pflugerville, Texas.
    → Acquiring early-stage clinical pharmacology capacity expands FTRE contract research capacity in early-phase trial execution.
    Impact
    Fortrea announced a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The transaction expands Fortrea's early clinical development footprint, adding a GLP-compliant bioanalytical lab in Austin, a 200-bed clinical pharmacology facility in San Antonio, and specimen storage assets in Pflugerville, Texas.
    Affected
    FTRE
    Transmission
    Acquiring early-stage clinical pharmacology capacity expands FTRE contract research capacity in early-phase trial execution.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    FTREearly-phase clinical trial capacity expansionUp1-4wFortrea signed definitive agreement to acquire Early Phase Services division for ~$45 million.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month